

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2,A32; B49, B64; Cw7,Cw8; DR7, DR13; DQ2, DQ6

Summary of Results					Summary of Results				
Total tested	21	21	21	21	18	18	18	18	
Positive	0	3	3	0	0	2	3	0	
Negative	21	18	18	21	18	16	15	18	
Not Tested	2	2	2	2	2	2	2	2	
% Positive	0.0%	14.3%	14.3%	0.0%	0.0%	11.1%	16.7%	0.0%	
% Negative	100.0%	85.7%	85.7%	100.0%	100.0%	88.9%	83.3%	100.0%	
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Cw2	DQ1	DR52	A9, DR15					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Short staffed.
11	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Short staffed.
14	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
15	NT	NT	NT	NT	NT	NT	NT	NT	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23	Negative	Negative	Negative	Negative					
24	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
35	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
38	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
39	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
41	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Negative	
42	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
45	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
48	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
54	Negative	Negative	Negative	Negative					
58	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
62	Negative	Negative	Negative	Negative					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 16TH SEPTEMBER 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	4	0	0	0	4	0	0	16-Jul	17-Jul	Yes	Yes	90	Cedarlane	30	30	AO/PI	
11									16-Jul	17-Jul	Yes	Yes	95	Cedarlane	45	90	Fluoroquenched	
12	5%	5%	5%	5%	5%	5%	5%	5%	16-Jul	16-Jul	Yes	No	95	Cedarlane	30	90	EB/AO	
14	0	0	0	0	0	0	0	0	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	60	120	EB/AO	
15	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
20	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	30	60	EB/AO	
23	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	>90	Cedarlane	40	40	EB/AO	
24	20%	20%	20%	20%	20%	20%	20%	20%	16-Jul	17-Jul	Yes	Yes	90	Cedarlane	45	90	Fluoroquenched	
25	1	1	1	1	1	1	1	1	17-Jul	17-Jul	Yes	Yes	99	Cedarlane	45	60	Fluoroquenched	
28	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes	Yes	95	Cedarlane	30	45	EB/AO	
34	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	99	Cedarlane	30	90	EB/AO	
35	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes	Yes	80	70	Cedarlane	60	120	Fluoroquenched
38	1	2	2	1	1	2	2	1	16-Jul	16-Jul	Yes	Yes	99	99	Cedarlane	60	60	EB/AO
39			2				2		16-Jul	16-Jul	Yes	No	99	Cedarlane	45	90	EB/AO	
41	5%	20%	20%	5%					16-Jul	16-Jul	Yes	No	95	Cedarlane	60	60	EB/AO	
42									16-Jul	16-Jul	Yes	No	95	TCS Biosciences	60	120	EB/AO	
45	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	99	Cedarlane	60	90	EB/AO	
48									16-Jul	16-Jul	Yes	No	90	Cedarlane	30	60	EB	
51	0	0	0	0	0	0	0	0	16-Jul	17-Jul	Yes	Yes	95	Cedarlane	60	60	Fluoroquenched	
54	0%	10%	10%	0%					16-Jul	17-Jul	Yes	Yes	95	Cedarlane	60	60	PI	
58	5%	5%	5%	5%	5%	55%	5%	5%	16-Jul	16-Jul	Yes	Yes	95	Cedarlane	60	90	Fluoroquenched	
62	1	1	1	1					16-Jul	16-Jul	Yes	Yes	99	Cedarlane	60	120	EB/AO	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2,A32; B49, B64; Cw7,Cw8; DR7, DR13; DQ2, DQ6

Summary of Results					Summary of Results				
Total tested	19	19	19	19	16	16	14	15	
Positive	3	18	18	3	0	16	14	2	
Negative	16	1	1	16	16	0	0	13	
Not Tested	2	2	2	2	2	2	3	3	
% Positive	15.8%	94.7%	94.7%	15.8%	0.0%	100.0%	100.0%	13.3%	
% Negative	84.2%	5.3%	5.3%	84.2%	100.0%	0.0%	0.0%	86.7%	
Consensus	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
HLA Antibody (Defined By CDC)	Cw2	DQ1	DR52	A9, DR15					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Positive	Positive	Negative	Negative	Positive	NT	Negative	Serum 3 with DTT - NT due to low cell count.
11	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
12	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
14	Positive	Positive	Positive	Positive	Negative	Positive	Positive	Positive	
15	NT	NT	NT	NT	NT	NT	NT	NT	Short staffed.
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
23	Negative	Positive	Positive	Negative					
24	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
25	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
28	Negative	Positive	Positive	Negative	Negative	Positive	Inconclusive	Negative	
34	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
38	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
39	Positive	Positive	Positive	Positive	Negative	Positive	Positive	Positive	
41	Negative	Positive	Positive	Negative	Negative	Positive	Positive	NT	
42	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
45	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
51	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
54	Positive	Positive	Positive	Positive					
58	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
62	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 16TH SEPTEMBER 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	0	6	4	0	0	6	-	0	16-Jul	17-Jul	Yes	90	Cedarlane	30	30	AO/PI
11		>80%	>80%			>80%	>80%		16-Jul	17-Jul	Yes	95	Cedarlane	45	90	Fluoroquench
12	5%	100%	100%	5%	5%	100%	100%	5%	16-Jul	16-Jul	Yes	90	Cedarlane	30	60	EB/AO
14	4	8	8	6	0	8	8	6	16-Jul	16-Jul	Yes	95	Cedarlane	60	120	EB/AO
15	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
20	1	9	9	1	1	9	9	1	16-Jul	16-Jul	Yes	95	Cedarlane	30	60	EB/AO
23	1	8	6	1					16-Jul	16-Jul	Yes	>90	Cedarlane	40	40	EB/AO
24	30%	80%	90%	30%	20%	80%	90%	30%	16-Jul	17-Jul	Yes	80	Cedarlane	45	90	Fluoroquench
25	1	6	8	1	1	6	8	1	17-Jul	17-Jul	Yes	99	Cedarlane	45	60	Fluoroquench
28	1	8	8	1	1	8	0	1	16-Jul	17-Jul	Yes	85	Cedarlane	30	45	EB/AO
34	1	8	8	1	1	8	8	1	16-Jul	16-Jul	Yes	97	Cedarlane	30	90	EB/AO
38	1	8	8	1	1	8	8	1	16-Jul	16-Jul	Yes	90	Cedarlane	60	60	EB/AO
39	2	8	8	4		8	8	8	16-Jul	16-Jul	Yes	98	Cedarlane	45	90	EB/AO
41	5%	95%	95%	5%					16-Jul	16-Jul	Yes	90	Cedarlane	45	45	EB/AO
42		80-100%	80-100%			80-100%	80-100%		16-Jul	16-Jul	Yes	90	TCS Biosciences	60	120	EB/AO
45	1	8	8	1	1	8	8	1	16-Jul	17-Jul	Yes	95	Cedarlane	30	75	EB/AO
51	0	8	8	0	0	8	8	0	16-Jul	17-Jul	Yes	95	Cedarlane	60	60	Fluoroquench
54	60%	100%	100%	70%					16-Jul	17-Jul	Yes	80	Cedarlane	60	60	PI
58	5%	100%	100%	5%	5%	100%	100%	30%	16-Jul	16-Jul	Yes	95	Cedarlane	60	90	Fluoroquench
62	1	1	1	1					16-Jul	16-Jul	Yes	75	Cedarlane	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate